CTOs on the Move


 
Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million
  • www.pronutriabio.com
  • 840 Memorial Drive, Third Floor Entrance on Blackstone Street
    Cambridge, MA USA 02139
  • Phone: 617.868.0949

Executives

Name Title Contact Details

Funding

Pronutria raised $39M on 05/28/2015

Similar Companies

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.

Neurotrack

Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.